Nephros, Inc. (NEPH)

Nephros, Inc.'s stock has experienced significant movement over the past six months. The share price saw a substantial increase of 208.44% from January 3, 2025, to January 2, 2026. Investor sentiment improved in December 2025, leading to a 19% stock rise, following a 15% fall in November 2025. The company reported its third-quarter 2025 earnings on November 8, 2025, with EPS and revenues exceeding analyst expectations. In October 2025, the launch of a new PFAS filtration solution was a notable event. In August 2024, the company announced its second-quarter 2024 financial results, reporting an 8% decrease in net revenue compared to Q2 2023, leading to an 8.20% decline in NEPH's stock on the day of the announcement.

Explicit information regarding demand seasonality for Nephros, Inc.'s products and services is not available. The company's business model relies on a recurring revenue stream from the sale of proprietary water filtration products and the mandatory replacement of disposable cartridges, suggesting a relatively stable and consistent demand rather than significant seasonality.

Nephros, Inc. is a water technology company in the Health Care sector, focusing on medical and commercial filtration solutions within the United States. The company's core business revolves around advanced water filtration and infection control solutions. Its major products include ultrafiltration products used in dialysis centers and hospitals. For commercial markets, Nephros manufactures and sells water filters under the Nephros and AETHER brands. In late 2025, Nephros also launched a new PFAS filtration solution. The company's business model emphasizes a recurring revenue stream from the sale of filter systems and subsequent mandatory reorders of disposable cartridges.

Nephros, Inc. primarily develops and sells its water solutions to medical and commercial markets in the United States. Historically, there has also been distribution of its dialysis ultrafilters to U.S. and Canadian dialysis clinics.

Nephros, Inc. has maintained a generally positive brand reputation over the past year, largely driven by strong financial performance and product innovation. The company has received a consensus rating of "Moderate Buy" from analysts. Its third-quarter 2025 earnings exceeded analyst expectations, and the company achieved its highest level of programmatic sales, contributing to positive investor sentiment. The launch of a new PFAS filtration solution in late 2025 also positively impacted its reputation. While the second-quarter 2024 saw an 8% decrease in overall net revenue and a negative market reaction, the growth in programmatic revenue and new accounts helped mitigate the impact.

Nephros, Inc. is a publicly traded company with ownership distributed among institutional investors, individual insiders, and the general public. Approximately 41.10% to 46.44% of the company's stock is held by institutional investors, while individual insiders hold around 3.03% to 12.9%, and the general public/retail investors hold approximately 39.9% to 50.53%. Major institutional and individual owners are listed.